Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015)

Despierre, E; Vergote, I; Anderson, R; Coens, C; Katsaros, D; Hirsch, Fr; Boeckx, B; Varella-Garcia, M; Ferrero, A; Ray-Coquard, I; Green, Ja; Steer, C; Emjj, Berns; Casado, A; Lambrechts, D; Jimeno, A

doi:10.1007/s11523-016-0433-x

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015)

Despierre E;Vergote I;Anderson R;Coens C;Katsaros D;Hirsch FR;Boeckx B;Varella-Garcia M;Ferrero A;Ray-Coquard I;Green JA;Steer C;Berns EMJJ;Casado A;Lambrechts D;Jimeno A

2016-01-01

Scheda breve

Scheda completa

Scheda completa (DC)

	Anno
	
			2016
		
	Titolo rivista
	
			TARGETED ONCOLOGY
		
	N. Volume
	
			11
		
	Fascicolo
	
			3
		
	Pagine (da)
	
			429
		
	Pagine (a)
	
			429
		
	DOI
	
			https://dx.doi.org/10.1007/s11523-016-0433-x
		
	Tutti gli autori
	
			Despierre E; Vergote I; Anderson R; Coens C; Katsaros D; Hirsch FR; Boeckx B; Varella-Garcia M; Ferrero A; Ray-Coquard I; Green JA; Steer C; Berns EMJJ; Casado A; Lambrechts D; Jimeno A
		
	Appare nelle tipologie:
	
			03A-Articolo su Rivista

File in questo prodotto:

Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1904379

Citazioni

ND

1

1

CINECA IRIS Institutional Research Information System

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015)

Despierre E;Vergote I;Anderson R;Coens C;Katsaros D;Hirsch FR;Boeckx B;Varella-Garcia M;Ferrero A;Ray-Coquard I;Green JA;Steer C;Berns EMJJ;Casado A;Lambrechts D;Jimeno A

2016-01-01

Scheda breve

Scheda completa

Scheda completa (DC)

Citazioni

social impact

CINECA IRIS Institutional Research Information System

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (vol 10, pg 583, 2015)

Despierre E;Vergote I;Anderson R;Coens C;Katsaros D;Hirsch FR;Boeckx B;Varella-Garcia M;Ferrero A;Ray-Coquard I;Green JA;Steer C;Berns EMJJ;Casado A;Lambrechts D;Jimeno A

2016-01-01

Scheda breve Scheda completa Scheda completa (DC)

Informazioni

Citazioni

social impact

Conferma cancellazione

Scheda breve

Scheda completa

Scheda completa (DC)